Literature DB >> 25264294

Integrin adjunct therapy for melanoma.

Kumari L Andarawewa1, Konstadinos Moissoglu, Chang Sup Lee, Yuta Ando, Min Yu, Prianka Debnath, John D Shannon, Suseela Sirinivasan, Mark R Conaway, Michael J Weber, Martin A Schwartz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25264294      PMCID： PMC6542633          DOI： 10.1111/pcmr.12320

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  11 in total

1.  Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation.

Authors:  Georgette Thumshirn; Ulrich Hersel; Simon L Goodman; Horst Kessler
Journal:  Chemistry       Date:  2003-06-16       Impact factor: 5.236

2.  Integrin expression in human melanoma cells with differing invasive and metastatic properties.

Authors:  K R Gehlsen; G E Davis; P Sriramarao
Journal:  Clin Exp Metastasis       Date:  1992-03       Impact factor: 5.150

3.  Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands.

Authors:  Elisabeth Garanger; Didier Boturyn; Jean-Luc Coll; Marie-Christine Favrot; Pascal Dumy
Journal:  Org Biomol Chem       Date:  2006-04-03       Impact factor: 3.876

4.  Insoluble fibronectin activates the Na/H antiporter by clustering and immobilizing integrin alpha 5 beta 1, independent of cell shape.

Authors:  M A Schwartz; C Lechene; D E Ingber
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

Review 5.  Integrins: emerging paradigms of signal transduction.

Authors:  M A Schwartz; M D Schaller; M H Ginsberg
Journal:  Annu Rev Cell Dev Biol       Date:  1995       Impact factor: 13.827

6.  Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition.

Authors:  Kumari L Andarawewa; Anna C Erickson; William S Chou; Sylvain V Costes; Philippe Gascard; Joni D Mott; Mina J Bissell; Mary Helen Barcellos-Hoff
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

7.  Integrin agonists as adjuvants in chemotherapy for melanoma.

Authors:  Martin A Schwartz; Kevin McRoberts; Matthew Coyner; Kumari L Andarawewa; Henry F Frierson; John M Sanders; Stephen Swenson; Frank Markland; Mark R Conaway; Dan Theodorescu
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

8.  Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2.

Authors:  Kerrington R Molhoek; Heinrich Griesemann; Jianfen Shu; Jeffrey E Gershenwald; David L Brautigan; Craig L Slingluff
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

9.  The extracellular matrix in pigmented skin lesions: an immunohistochemical study.

Authors:  C M Van Duinen; G J Fleuren; J A Bruijn
Journal:  Histopathology       Date:  1994-01       Impact factor: 5.087

10.  Trimers of the fibronectin cell adhesion domain localize to actin filament bundles and undergo rearward translocation.

Authors:  Françoise Coussen; Daniel Choquet; Michael P Sheetz; Harold P Erickson
Journal:  J Cell Sci       Date:  2002-06-15       Impact factor: 5.285
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.